New insights into core biological processes promise unprecedented potential to transform human health, but only if interventional agents can be delivered to the site of action.

Qana is pioneering a targeted delivery technologies based on the human body’s own systems for transporting critical payloads to their destinations.

We are turning today’s laboratory discoveries into tomorrow’s cures.

Qana’s peptide-targeted nanoparticle delivery platform builds upon decades of research on the endogenous cholesterol transport system – an intricate network of carriers and receptors sending billions of particles to their destinations each day.

Our platform exploits the body’s own delivery machinery to deliver challenging payloads to their site of action. This approach has the potential to address many of the limitations of today’s delivery technologies and to enhance novel medicines.

• Metabolic reprogramming has emerged as a potential therapeutic target for fighting cancer

• We are developing a receptor-restricted carrier particle against surface targets related to PI3K / Akt / mTOR pathway activation

• Over-expression of surface markers of tumor metabolism has been observed and documented in multiple tumor types, and has been shown to be required for tumor growth in a subset of tumors.

• Based on observed expression and potential therapeutic application, millions of cancer patients could benefit from this novel approach to anti-tumor therapy